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Abstract
To assess the time it takes for a real-time PCR to become negative
after treatment of a Giardia lamblia infection, we evaluated two
consecutive follow-up samples from 75 infected patients. Approx-
imately 1 week after treatment all samples tested negative,
indicating rapid clearance of parasitic DNA after successful
treatment.
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Introduction
Giardia lamblia is a protozoan parasite causing diarrhoea in
individuals worldwide. The estimated prevalence in industrial-
ized countries is c. 2% for adults and 6–8% for children [1].
Three Dutch studies detected G. lamblia DNA in 5.8–11.1% of
samples taken from patients presenting with gastrointestinal
symptoms [2]. Traditionally, microscopy is the diagnostic
method of choice, although sensitivity is known to vary
depending on the number of samples examined, the experi-
ence of the microscopist and the use of concentration
techniques [3]. Direct ﬂuorescent antibody (DFA) and
ELISA-based methods are sensitive and cost-effective [4,5],
although, like microscopy, time consuming and laborious.
Lately, real-time PCR was introduced to the clinical microbi-
ology laboratory for diagnosis of parasitic intestinal infections.
It has a signiﬁcantly higher detection rate for G. lamblia
compared with traditional microscopy and allows automation
and simultaneous detection of different targets [2,3,6]. A highly
relevant question accompanying molecular diagnostics is how
long parasitic DNA can be detected after successful treatment.
In patients with persistent symptoms the differentiation
between therapy failure and detection of DNA of non-viable
parasites is important for further treatment. G. lamblia is
non-invasive and attaches to the mucosa of the small intestine
where it undergoes asexual replication. As the estimated
turnover time of the intestinal mucosa is 2–4 days, we
hypothesize that the real-time PCR on faecal samples becomes
negative within 1 week after successful treatment.
To conﬁrm this hypothesis we performed a prospective
study at the St Elisabeth hospital Tilburg, the Netherlands.
Between January and October 2013, inpatients and outpatients
with a PCR-based diagnosis of G. lamblia were considered
eligible to participate if they had not received treatment so far.
Patients were informed of the diagnosis by their general
practitioner or attending specialist, who received information
concerning the study and advice on therapy (metronidazole;
2 g once daily for 3 days for adults, 50 mg/kg once daily for
3 days for children) from the consultant microbiologist.
Patients were asked to return consecutive stool samples after
treatment. Follow-up sample 1 (FU1) was requested at the end
of antibiotic treatment (EAT), follow-up sample 2 (FU2) 7 days
after FU1, and an optional follow-up sample 3 (FU3), 1 month
after FU1, was requested only if Giardia DNA was detected in
follow-up sample 2. Automated nucleic acid extraction using
QIAsymphony [7] and a multiplex real-time PCR for the
detection of G. lamblia, Entamoeba histolytica and Cryptosporidi-
um spp. [8,9] was performed on all samples within 24 h after
receipt of the sample. Statistical analysis was performed by
using SPSS version 19.0. (IBM Corp., Armonk, NY, USA).
Comparison of continuous variables was performed by using
the Mann–Whitney U-test, and comparison of binary data by
using Fisher’s exact test. This study was approved by the ethics
committee of the St Elizabeth Hospital, Tilburg, the Nether-
lands.
During the study period the multiplex PCR was performed
on samples from 2307 persons. One hundred and eleven
patients were found to be eligible for inclusion based on
Giardia DNA detection (positivity rate, 4.8%). Seventy-ﬁve
(67.6%) patients were willing to participate. There was no
difference in the age (p 0.818) and initial Cycle threshold (Ct)
value (p 0.415) of the participating patients compared with the
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36 non-participating patients. For 10 patients no FU2 samples
were received so only FU1 data were included in the analysis.
Giardia DNA was detected in 30 of 75 FU1 samples (40.0%)
and in none of the 65 FU2 samples (0.0%) (Fig. 1), therefore no
FU3 samples were requested. The median time between EAT
to FU1 was 1 day (range 0–22 days) and the median time
between FU1 and FU2 was 7 days (range 4–22 days). Ninety
per cent of all samples were received within 4 and 10 days,
respectively. The absence of Giardia DNA in all FU2 samples
indicates a rapid clearance after treatment.
The Ct-values of the initial samples from patients who
tested negative at FU1 were signiﬁcantly higher than those for
patients who tested positive at FU1 (median 27.3 vs 23.0, p
0.001), indicating a lower parasitic load. Also the time interval
between EAT and FU1 differed signiﬁcantly between the two
groups (median 2 days vs 1 day, p 0.04). Age did not inﬂuence
the probability of a positive FU1 test (OR < 18 years vs
adults = 1.27, p 0.48).
Using a multiplex PCR, Cryptosporidium spp. DNA was
detected in 1.0%, 1.7% and 1.8% of the initial samples, FU1s
and FU2s, respectively. E. histolytica DNA was not detected
during the study period.
The rapid clearance of Giardia DNA in all patients is in
contrast to ﬁndings reported by Mejia et al. [6]. They
described that c. 65% of their treated study population
(albendazole/ivermectin for 3 days) cleared Giardia DNA after
21 days. This difference might be explained by a non-optimal
treatment regime or by the greater risk of re-infection due to a
high prevalence in the study area (Ecuador).
In other studies, 20% treatment failure after metronidazole
therapy, possibly caused by drug resistance, was reported,
especially in patients who acquired their infection in Asia [10–
12]. Although in the daily routine we sometimes encounter
Giardia infections in patients who do not respond to metro-
nidazol treatment, the 100% clearance rate found in the
present study period suggests that no treatment failure
occurred. This short-course molecular follow-up study for
G. lamblia infection can not exclude the possibility of inter-
mittent Giardia shedding; however, all patients who had
negative FU1 samples remained negative at FU2.
A limitation of our study is the treatment delay. Even
though we contacted the attending physician immediately after
PCR results were authorized, the median time between the
initial diagnosis and EAT was 5.5 days (range 2–19 days). As a
result of this treatment delay, some patients may have already
cleared G. lamblia as a natural course of infection, resulting in
negative FU1 samples. However, the time between the initial
diagnosis and the end of treatment was comparable in patients
FIG. 1. Flow-chart of inclusion, number of follow-up samples received and test results of this study.
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who tested positive and patients who tested negative at FU1
(median 5 vs 6 days, p 0.249).
Our study shows that shortly after treatment Giardia DNA
is undetectable in the stool, making a positive multiplex PCR
test 1 week after treatment a strong indication of renewed or
on-going infection. Probably, this does not only apply to
G. lamblia but also to other non-invasive parasitic infections.
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FIG. 2. Giardia lamblia DNA load before (Initial), immediately after (FU1) and 1 week after (FU2) treatment. Separate lines represent samples of
individual patients, dotted lines with X marks (n = 10) represent patients who only returned FU1. 1/CT = 1/cycle threshold, 1/CT <0.020 is
considered negative.
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